OPUS GENETICS INC(IRD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IRD OPUS GENETICS INC

Trading 10-23 14:05:54 EDT

3.50

-0.32

-8.51%

High3.80	Low3.49	Vol600.22K
Open3.79	D1 Closing3.82	Amplitude8.21%
Mkt Cap290.77M	Tradable Cap225.26M	Total Shares83.20M
T/O2.17M	T/O Rate0.93%	Tradable Shares64.45M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":3.495,"timestamp":1792778753585,"preClose":3.82,"halted":0,"volume":600215,"delay":0,"changeRate":-0.08507853403141355,"floatShares":64451400,"shares":83195823,"eps":-1.292468,"marketStatus":"Trading","change":-0.325,"latestTime":"10-23 14:05:54 EDT","open":3.79,"high":3.8038,"low":3.49,"amount":2167868.3612355,"amplitude":0.082147,"askPrice":3.5,"askSize":804,"bidPrice":3.49,"bidSize":900,"shortable":3,"etf":0,"ttmEps":-1.292468,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1792785600000},"marketStatusCode":2,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":3.82,"preHourTrading":{"tag":"盘前","latestPrice":3.76,"preClose":3.82,"latestTime":"09:25 EDT","volume":614,"amount":2315.1124196,"timestamp":1792761938738,"change":-0.06,"changeRate":-0.015707,"amplitude":0.072382},"postHourTrading":{"tag":"盘后","latestPrice":3.79,"preClose":3.82,"latestTime":"19:30 EDT","volume":5137,"amount":19573.6721,"timestamp":1792711801656,"change":-0.03,"changeRate":-0.007853,"amplitude":0.01966},"volumeRatio":0.545688,"impliedVol":2.0648,"impliedVolPercentile":0.6295},"requestUrl":"/m/hq/s/IRD/wiki","defaultTab":"wiki","newsList":[{"id":"2677965812","title":"Opus Genetics is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2677965812","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677965812?lang=en_us&edition=fundamental","pubTime":"2026-10-22 20:57","pubTimestamp":1792673820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677660257","title":"Opus Genetics Chief Scientific and Development Officer Ashwath Jayagopal Steps Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2677660257","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677660257?lang=en_us&edition=fundamental","pubTime":"2026-10-22 04:16","pubTimestamp":1792613766,"startTime":"0","endTime":"0","summary":"Opus Genetics Chief Scientific and Development Officer Ashwath Jayagopal Steps DownOpus Genetics Chief Scientific and Development Officer Ashwath Jayagopal will step down effective October 19, 2026.Ja","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261021:nNDL3h2Lv6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677673690","title":"Opus Genetics Gets FDA Clearance to Test OPGx-RDH12 Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2677673690","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677673690?lang=en_us&edition=fundamental","pubTime":"2026-10-21 19:06","pubTimestamp":1792580810,"startTime":"0","endTime":"0","summary":"Opus Genetics Gets FDA Clearance to Test OPGx-RDH12 Gene TherapyFDA cleared Opus Genetics' investigational new drug application for OPGx-RDH12, a gene therapy targeting RDH12-associated Leber congenit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261021:nNDL6g01t6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","IE00B3QW5Z07.USD","BK4112","IE00BKPKM429.USD","BK4588","LU0314104364.USD","IE00BN0W2W23.USD","BCDF","SG9999014039.USD","SG9999014021.USD","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","BK4007","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","BK4139","IRD","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677678062","title":"Opus Genetics Announces FDA Clearance of Ind Application for Opgx-Rdh12 Gene Therapy for Inherited Childhood Blindness","url":"https://stock-news.laohu8.com/highlight/detail?id=2677678062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677678062?lang=en_us&edition=fundamental","pubTime":"2026-10-21 19:00","pubTimestamp":1792580401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261021:nTUA5CMZKZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677467804","title":"Opus Genetics - to Initiate Phase 1/2 Trial of Opgx-Rdh12 This Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2677467804","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677467804?lang=en_us&edition=fundamental","pubTime":"2026-10-21 19:00","pubTimestamp":1792580401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261021:nTUA5CMZKZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676158745","title":"Opus Genetics Wins FDA Approval for Ryzumvi to Treat Presbyopia in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2676158745","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676158745?lang=en_us&edition=fundamental","pubTime":"2026-10-17 00:00","pubTimestamp":1792166448,"startTime":"0","endTime":"0","summary":"Opus Genetics Wins FDA Approval for Ryzumvi to Treat Presbyopia in AdultsOpus Genetics secured FDA clearance for Ryzumvi, phentolamine ophthalmic solution 0.75%, to treat presbyopia in adults, expandi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nNDL6tWSqv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014021.USD","SG9999014005.SGD","BCDF","LU2210150020.SGD","BK4007","SG9999014013.SGD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","IE00BQXX3F31.USD","IE00BQXX3D17.EUR","LU2210149790.SGD","IRD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BGHQF748.EUR","BK4112","NDAQ","IE00BQXX3C00.GBP","LU2095319765.USD","IE00BN0W2V16.EUR","BK4139","BK4588","BK4585","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676515879","title":"Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia","url":"https://stock-news.laohu8.com/highlight/detail?id=2676515879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676515879?lang=en_us&edition=fundamental","pubTime":"2026-10-17 00:00","pubTimestamp":1792166400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nTUA1TCCDW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675853768","title":"Opus Genetics' OPGx-BEST1 Improves Retinal Sensitivity in 75% of Evaluable Patients in Early-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2675853768","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675853768?lang=en_us&edition=fundamental","pubTime":"2026-10-16 04:00","pubTimestamp":1792094437,"startTime":"0","endTime":"0","summary":"Opus Genetics' OPGx-BEST1 improves retinal sensitivity in 75% of evaluable patients in early-stage trialOpus Genetics presented positive clinical results for its OPGx-LCA5 and OPGx-BEST1 gene therapie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261015:nNDL20nLZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00B64PRP62.GBP","BK4112","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ","LU2210150020.SGD","BK4588","IRD","IE00BN0W2W23.USD","IE00BQXX3F31.USD","IE00BQXX3D17.EUR","BK4585","SG9999014021.USD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2210149790.SGD","BK4139","LU2095319765.USD","SG9999014005.SGD","BCDF","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675550803","title":"Opus Genetics Presents at Chardan Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2675550803","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675550803?lang=en_us&edition=fundamental","pubTime":"2026-10-13 19:03","pubTimestamp":1791889398,"startTime":"0","endTime":"0","summary":"Opus Genetics presents at Chardan Annual Healthcare ConferenceOpus Genetics management will present at the Chardan Annual Healthcare Conference on Oct. 20, 2026 at 10:00 a.m. ET.Disclaimer:This news b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nNDL5Ttmrz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014039.USD","BK4139","IE00BGHQF748.EUR","LU2095319765.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","BK4585","BK4112","IE00BQXX3C00.GBP","IRD","BCDF","LU0314104364.USD","SG9999014021.USD","IE00BN0W2W23.USD","SG9999014005.SGD","NDAQ","IE00BQXX3F31.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673032617","title":"US Research Roundup-Affiliated Managers Group, Goldman Sachs, Vaxcyte","url":"https://stock-news.laohu8.com/highlight/detail?id=2673032617","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673032617?lang=en_us&edition=fundamental","pubTime":"2026-10-06 16:10","pubTimestamp":1791274226,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, VaxcyteOct 6 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nL4N45S0HY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CWH","BAM","NTAP","EXE","ELMT","CG","APO","IBKR","AAUM","FHI","GSHD","GSX","PLMR","KBWB","NXH","BX","IRD","ALL","HBAN","KNSL","CTVA","BAH","HIPO","LBO","NKE","IAI","GS","PUI","STYL","LPLA","OKE","PLSE","PBJ","ICE","PSN","ARES","PCVX","FCPT","IVZ","OHI","AADX","LDOS","AB","BLK","LMND","PS","PSP","PTC","KKR","AMG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673003529","title":"Opus Genetics Inc : Jonestrading Raises Target Price to $17 from $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2673003529","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673003529?lang=en_us&edition=fundamental","pubTime":"2026-10-06 12:10","pubTimestamp":1791259842,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nFWN45R1D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672744174","title":"Foundation Fighting Blindness Retinal Degeneration Fund Disposes of Opus Genetics Common Shares Worth $2,756,020.80","url":"https://stock-news.laohu8.com/highlight/detail?id=2672744174","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672744174?lang=en_us&edition=fundamental","pubTime":"2026-10-03 07:47","pubTimestamp":1790984863,"startTime":"0","endTime":"0","summary":"Foundation Fighting Blindness Retinal Degeneration Fund disposes of Opus Genetics common shares worth $2,756,020.80Foundation Fighting Blindness Retinal Degeneration Fund sold 556,000 Opus Genetics co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDLcbk8yN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Foundation Fighting Blindness Retinal Degeneration Fund Disposes of Opus Genetics Common Shares Worth $2,756,020.80","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672305714","title":"Opus Genetics Price Target Maintained with a $16.00/Share by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2672305714","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672305714?lang=en_us&edition=fundamental","pubTime":"2026-10-02 20:28","pubTimestamp":1790944080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667502247","title":"LifeSci Capital Remains a Buy on Opus Genetics (IRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667502247","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667502247?lang=en_us&edition=fundamental","pubTime":"2026-09-13 01:15","pubTimestamp":1789233314,"startTime":"0","endTime":"0","summary":"In a report released today, Francois Brisebois from LifeSci Capital maintained a Buy rating on Opus Genetics, with a price target of $20.00. Briseb...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-opus-genetics-ird-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-opus-genetics-ird-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666226575","title":"Opus Genetics Posts OPGx-BEST1 Phase 1/2 Low-Dose Cohort Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2666226575","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666226575?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:50","pubTimestamp":1789131017,"startTime":"0","endTime":"0","summary":"Opus Genetics posts OPGx-BEST1 Phase 1/2 low-dose cohort presentationOpus Genetics released 3-month results from the low-dose Cohort 1 of its Phase 1/2 OPGx-BEST1 gene therapy study.Low-dose cohort re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL5bpnMC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666181055","title":"Health Rounds: Experimental Eye Drops Ease Night Vision Problems for Drivers","url":"https://stock-news.laohu8.com/highlight/detail?id=2666181055","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666181055?lang=en_us&edition=fundamental","pubTime":"2026-09-11 03:20","pubTimestamp":1789068011,"startTime":"0","endTime":"0","summary":"Health Rounds: Experimental eye drops ease night vision problems for driversSept 10 -Hello Health Rounds readers!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nL1N4520WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666145562","title":"Thomas Shrader Reiterates Buy on IRD, Maintains $12 Price Target Amid Encouraging Clinical and Regulatory Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2666145562","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666145562?lang=en_us&edition=fundamental","pubTime":"2026-09-10 18:15","pubTimestamp":1789035355,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Opus Genetics, with a price target of $12.00. Thomas Shrader ha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/thomas-shrader-reiterates-buy-on-ird-maintains-12-price-target-amid-encouraging-clinical-and-regulatory-progress-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/thomas-shrader-reiterates-buy-on-ird-maintains-12-price-target-amid-encouraging-clinical-and-regulatory-progress-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666012532","title":"Opus Genetics up over 32%, on Track for Largest Percent Increase Since February 2020","url":"https://stock-news.laohu8.com/highlight/detail?id=2666012532","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666012532?lang=en_us&edition=fundamental","pubTime":"2026-09-10 02:46","pubTimestamp":1788979560,"startTime":"0","endTime":"0","summary":"Opus Genetics, Inc.  is currently at $5.74, up $1.40 or 32.14%--Would be highest close since April 17, 2026, when it closed at $5.75--On pace for largest percent increase since Feb. 11, 2020, when it rose 79.31%--Currently up five of the past six days--Up 58.43% month-to-date--Up 185.32% year-to-date--Down 99.94% from its all-time closing high of $10080.00 on Dec. 15, 2004--Up 331.2% from 52 weeks ago , when it closed at $1.33--Down 0.26% from its 52-week closing high of $5.75 on April 17, 2026--Up 331.2% from its 52-week closing low of $1.33 on Sept. 10, 2025--Traded as high as $7.07; highest intraday level since April 5, 2021, when it hit $7.28--Up 62.9% at today's intraday high; largest intraday percent increase since June 2, 2025, when it rose as much as 75.97%All data as of 2:44:02 PM ETSource: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666162532","title":"Opus Genetics Reach 52-Week High on Clinical Trial, FDA Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2666162532","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666162532?lang=en_us&edition=fundamental","pubTime":"2026-09-10 02:08","pubTimestamp":1788977280,"startTime":"0","endTime":"0","summary":"Shares of Opus Genetics, which focuses on inherited retinal diseases, reached a 52-week high as it reported favorable drug study data and a successful meeting with the Food and Drug Administration.The","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2065732104.USD","IRD","BK4139","BK4097","BK4588","PRGS","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666532138","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2666532138","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666532138?lang=en_us&edition=fundamental","pubTime":"2026-09-10 02:05","pubTimestamp":1788977158,"startTime":"0","endTime":"0","summary":"SUNation Energy  shares surged 60% after Suniva reported late Tuesday the close of an $835 million capital raise. The duo struck a reverse merger deal in June.Intraday trading volume catapulted to over 70.8 million from a daily average of about 2.5 million.InnovAge  swung to a profit in fiscal Q4 following a better-than-expected sales growth.Shares jumped 8%, with intraday trading volume rising to over 612,000 from a daily average of about 317,000.Opus Genetics  said Wednesday patients with BEST1-related retinal diseases showed clinically meaningful improvement in visual function in the low-dose cohort 1 of its BIRD-1 phase 1/2 clinical trial evaluating OPGx-BEST1.Wedbush Securities raised its price target for the stock to $13 from $10 while maintaining its outperform rating.Shares surged 25% as intraday trading volume soared to over 43.6 million from a daily average of roughly 1.1 million.Price: 3.85, Change: +1.48, Percent Change: +62.24","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["INNV","BK4564","MARS","LU0054578231.USD","IRD.AU","ROKT","BK4196","COWG","ORBX","BK4007","IRDM","IRD","BK4089","BK7129","DIPR","BK4139","XTL","BK4096","SUNE","WARP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocuphire.com;ir.opusgtx.com;www.opusgtx.com","stockEarnings":[{"period":"1week","weight":-0.0568},{"period":"1month","weight":-0.2597},{"period":"3month","weight":0.2403},{"period":"6month","weight":-0.2696},{"period":"1year","weight":0.959},{"period":"ytd","weight":0.9005}],"compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.0122},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.0701},{"period":"1year","weight":0.144},{"period":"ytd","weight":0.1203}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.077612},{"month":2,"riseRate":0.5,"avgChangeRate":0.090887},{"month":3,"riseRate":0.363636,"avgChangeRate":0.009762},{"month":4,"riseRate":0.428571,"avgChangeRate":0.498458},{"month":5,"riseRate":0.590909,"avgChangeRate":4.154221},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.020512},{"month":7,"riseRate":0.363636,"avgChangeRate":0.000717},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.018884},{"month":9,"riseRate":0.5,"avgChangeRate":0.01044},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.088124},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.065655},{"month":12,"riseRate":0.454545,"avgChangeRate":0.054326}],"exchange":"NASDAQ","name":"OPUS GENETICS INC","nameEN":"OPUS GENETICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OPUS GENETICS INC(IRD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OPUS GENETICS INC(IRD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OPUS GENETICS INC,IRD,OPUS GENETICS INC股票,OPUS GENETICS INC股票老虎,OPUS GENETICS INC股票老虎国际,OPUS GENETICS INC行情,OPUS GENETICS INC股票行情,OPUS GENETICS INC股价,OPUS GENETICS INC股市,OPUS GENETICS INC股票价格,OPUS GENETICS INC股票交易,OPUS GENETICS INC股票购买,OPUS GENETICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OPUS GENETICS INC(IRD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OPUS GENETICS INC(IRD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}